Introns: Clinical Trials

25 trials of Introns, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 5 terminated, 1 withdrawn. 25 Phase 1, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 125Completed 19, Terminated 5, Withdrawn 1
Phase 29Completed 5, Terminated 3, Withdrawn 1

Follow Introns: new trials by email Literature Review of Introns trials Research Report on Introns

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute42020-11-172026-01-13
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Phase 1CompletedRoswell Park Cancer Institute92019-12-062023-09-11
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b - Breastcancer, Breast Neoplasm
Phase 1 / Phase 2CompletedBriaCell Therapeutics Corporation242017-05-052021-01-29
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers
Human Serum Albumin/interferon alpha2b, Peginterferon 180 μg single dose S.C. - Healthy
Phase 1CompletedTianjin SinoBiotech Ltd.342016-04-072017-05-08
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
Pembrolizumab and high dose interferon alfa-2b (HDI) - Melanoma
Phase 1CompletedYana Najjar312015-03-062021-02-24
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
DC vaccine, Celecoxib, Interferon Alfa-2b - Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma
Phase 1 / Phase 2CompletedDavid Bartlett642014-07-012020-07-20
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Vemurafenib, IL-2, Interferon Alpha-2b - Melanoma
Phase 1CompletedM.D. Anderson Cancer Center62013-07-182019-05-21
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Ipilimumab, Temozolomide, Cisplatin - Melanoma
Phase 1TerminatedM.D. Anderson Cancer Center192013-02-012017-05-31
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute152012-10-012023-10-27
Multiple Antigen-Engineered DC Vaccine for Melanoma
DC Vaccine + IFN, AdVTMM2/DC Vaccination - Melanoma
Phase 1CompletedLisa H. Butterfield, Ph.D.352012-06-012017-08-31
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
Ipilimumab, Interferon, Interleukin-2 (Aldesleukin) - Melanoma
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2011-10-012012-01-26
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
Biochemo + bevacizumab then ipilimumab - Metastatic Melanoma
Phase 1 / Phase 2CompletedCalifornia Pacific Medical Center Research Institute242010-12-012013-08-29
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
Interferon Alfa-2b - Hepatitis C
Phase 1CompletedUniversity of North Carolina, Chapel Hill222010-05-012016-11-15
A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C
Interferon α-5, Interferon-α5 plus Interferon-α 2b, Interferon α-2b (INTRON® A) - Chronic Hepatitis C Virus Infection, Genotype 1
Phase 1 / Phase 2CompletedDigna Biotech S.L.702010-05-012013-02-05
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
Temozolomide, Abraxane, Cisplatin - Melanoma
Phase 1CompletedM.D. Anderson Cancer Center102009-09-012013-01-03
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
Pegylated Alfa Interferon, sunitinib, erlotinib - Carcinoma, Renal Cell
Phase 1 / Phase 2TerminatedThe Methodist Hospital Research Institute102007-05-012016-03-17
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
recombinant interferon alfa-2b, cisplatin, sodium stibogluconate - Stage IV Melanoma
Phase 1CompletedCase Comprehensive Cancer Center222007-05-012020-07-24
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Sodium Stibogluconate, Interferon Alpha-2b - Advanced Cancer, Solid Tumors
Phase 1CompletedM.D. Anderson Cancer Center332006-09-132018-11-15
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
recombinant interferon alfa-2b, azacitidine - Melanoma (Skin)
Phase 1CompletedUniversity of California, San Diego122006-02-012021-03-03
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
recombinant interferon alfa-2b, sodium stibogluconate, SSG & interferon - Cancer
Phase 1TerminatedThe Cleveland Clinic182005-10-012018-01-26

Showing 20 of 25. Sign in to see all of them.

Conditions studied

Melanoma (12)  ·  Recurrence (5)  ·  Carcinoma, Renal Cell (3)  ·  Neoplasm Metastasis (3)  ·  Breast Neoplasms (2)  ·  Neoplasms (2)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Breast Carcinoma In Situ (1)  ·  Carcinoma, Hepatocellular (1)  ·  Colorectal Neoplasms (1)  ·  Ependymoma (1)  ·  Glioblastoma (1)  ·  Glioma (1)  ·  Glioma, Subependymal (1)

Sponsors

M.D. Anderson Cancer Center (6)  ·  Roswell Park Cancer Institute (3)  ·  National Cancer Institute (NCI) (2)  ·  BriaCell Therapeutics Corporation (1)  ·  California Pacific Medical Center Research Institute (1)  ·  Case Comprehensive Cancer Center (1)  ·  David Bartlett (1)  ·  Digna Biotech S.L. (1)  ·  Endocyte (1)  ·  Lisa H. Butterfield, Ph.D. (1)  ·  The Cleveland Clinic (1)  ·  The Methodist Hospital Research Institute (1)  ·  The University of Hong Kong (1)  ·  Tianjin SinoBiotech Ltd. (1)  ·  University of California, San Diego (1)

Countries

United States (21)  ·  China (1)  ·  Spain (1)

Top investigators

Ernest C. Borden, MD (2)  ·  Rodabe N. Amaria, MD (2)  ·  Agop Y. Bedikian, MD,BS (1)  ·  Amer H Zureikat, MD (1)  ·  Ashish M. Kamat, MD (1)  ·  Aung Naing, MD (1)  ·  Chung Mau Lo, MS (1)  ·  David L Bartlett, MD (1)  ·  David R Minor, MD (1)  ·  George E Peoples, MD, FACS (1)  ·  Gregory A. Daniels, MD, PhD (1)  ·  Igor Puzanov (1)  ·  John M Kirkwood, MD (1)  ·  Mario Sznol (1)

Results publications

PMID 31014399

NIH funding

2009 (1), P01CA132714 (1), P30CA016056 (1), P30CA016058 (1), P30CA016672 (1), P30CA043703 (1), P50CA091846 (1), P50CA121973 (1), U01CA076576 (1), UL1TR001412 (1)